Exagen Past Earnings Performance

Past criteria checks 0/6

Exagen's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 7.5% per year.

Key information

-12.3%

Earnings growth rate

92.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate7.5%
Return on equity-104.4%
Net Margin-45.1%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Mar 26
Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Jul 21
Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Exagen appoints John Aballi as CEO

Oct 17

Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Aug 10
Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Jul 26
Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Apr 05
Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Dec 03
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Aug 06
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Apr 07
Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Mar 03
Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Exagen issues preliminary testing revenue ahead of ICT chat

Jan 11

Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Jan 05
Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Exagen (XGN) Investor Presentation - Slideshow

Nov 20

Revenue & Expenses Breakdown
Beta

How Exagen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:XGN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2353-24475
30 Sep 2352-32486
30 Jun 2353-35517
31 Mar 2346-45529
31 Dec 2246-47529
30 Sep 2245-40519
30 Jun 2243-39489
31 Mar 2248-31478
31 Dec 2148-27457
30 Sep 2148-23436
30 Jun 2147-20405
31 Mar 2143-17374
31 Dec 2042-17374
30 Sep 2040-17353
30 Jun 2039-29332
31 Mar 2041-31322
31 Dec 1940-30292
30 Sep 1940-31262
30 Jun 1938-18242
31 Mar 1935-18212
31 Dec 1832-18202
31 Dec 1727-33192
31 Dec 1518-21171
30 Sep 1518-21171
30 Jun 1517-23171
31 Mar 1515-17161
31 Dec 1412-17151
30 Sep 149-23131
30 Jun 146-21111
31 Mar 144-1991
31 Dec 133-1871

Quality Earnings: XGN is currently unprofitable.

Growing Profit Margin: XGN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: XGN is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare XGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: XGN has a negative Return on Equity (-104.38%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.